“…The inhibition was due primarily to a reduction in affinity, however, and not to a decreased rate constant for alkylation, suggesting perhaps that BR384 does not alkylate the D3.32 residue of M 1 and M 2 receptors. Nonetheless, the orthosteric muscarinic antagonist, NMS, competitively inhibited alkylation of wild type M 1 , wild type M 2 and the D103N mutant of the M 2 receptor by BR384, whereas the known allosteric modulator, gallamine, allosterically prevented alkylation (6, 8, 9). Thus, BR384 probably alkylates another residue within the orthosteric-binding pocket of the M 2 receptor.…”